Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. - Wikidata - awgldk - TriplyDB

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

http://www.wikidata.org/entity/Q33423263

about

Palbociclib - from Bench to Bedside and Beyond Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer CDK4/6 inhibition in luminal breast cancer Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Profile of palbociclib in the treatment of metastatic breast cancer The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer Novel Molecular Markers for Breast Cancer Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer ABC3 Consensus Commented from the Perspective of the German Guidelines Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Development of Companion Diagnostics Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer Other targeted drugs in melanoma Optimal management of hormone receptor positive metastatic breast cancer in 2016 Development of cell-cycle checkpoint therapy for solid tumors RB1: a prototype tumor suppressor and an enigma Targeted Therapies for Brain Metastases from Breast Cancer Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers Approaches to modernize the combination drug development paradigm Recent developments and translational aspects in targeted therapy for metastatic breast cancer Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies Toward precision medicine of breast cancer Developmental therapeutics for inflammatory breast cancer: Biology and translational directions Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant Major clinical research advances in gynecologic cancer in 2015 Recent advances in the medical treatment of breast cancer Targeting CDK4 and CDK6: From Discovery to Therapy Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer Inherited Disease Genetics Improves the Identification of Cancer-Associated Genes CDK4 is an essential insulin effector in adipocytes Implementing Genome-Driven Oncology.Cancer drug related cardiotoxicity during breast cancer treatment.ABC3 Consensus: Assessment by a German Group of Experts Same Data; Different Interpretations How may targeted proteomics complement genomic data in breast cancer?Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.Recent advances of highly selective CDK4/6 inhibitors in breast cancer

P2860

Q26738979-BDC07417-C2B0-4C0F-AFB4-E241ADEAFA9A Q26738982-10EE759E-F363-4348-88F6-286749F42154 Q26739836-53A4850B-E0D3-47CB-ABD3-D6C355E6F038 Q26741153-107780F1-EBC0-4E4A-9634-F64A4AD23E0C Q26747737-7CC8635C-0816-4FAD-BD81-B62C59E69A4F Q26751387-B18299C4-E2B1-4A2E-98D1-AD8F973A6F42 Q26753160-7298D67D-48E2-4BDA-872A-D5CDA7B1127A Q26764987-AD41518A-A382-43E1-A631-0F7676B1A651 Q26768665-055C3E77-2127-4B27-8D31-017C6E24249C Q26770482-573C446D-C3BB-4E15-912B-123FE307E452 Q26774670-4EE0CDB0-9480-4A2B-843A-4E94C625A221 Q26775361-1664AC77-DCCE-4E09-AC7B-0E47531F9773 Q26775594-448AA0B8-6A67-4259-8DEF-7240EFF04AA8 Q26777683-07596119-F5BA-4BF6-82D6-57288E6E6839 Q26781187-2FCF4C8B-D4E5-4E05-A6DB-9CF8DE808EFD Q26866393-F4D4EC6C-917E-4F56-805C-782D10D859ED Q28068154-029FCDF6-D894-44C3-9BCD-682EFE75A1AD Q28069910-B952AD1B-5591-463A-A3A1-5AA61EACFABF Q28072074-CC595E2E-C0DE-42FB-9B54-14B9A300AF73 Q28072755-4DABB310-4FFF-4D67-AAF2-D1981C4839D4 Q28072897-CF5DAF74-B301-47A8-BDD6-33AE4A4835C2 Q28073967-11D25B62-E2CD-4BDC-AC15-5A649A28B573 Q28075322-0713C50A-0667-40AC-BC1E-1422367C66F2 Q28076777-0E53E313-7B70-4FBF-936A-260FF35E7848 Q28077183-E2797FA9-398B-4347-8AF4-4B570E599363 Q28078951-BA324D72-927E-4868-B8EA-E79E7C6447F8 Q28082912-C5DD849C-1F31-4C2E-AFB1-A554E4AC80C5 Q28084585-C54FEF3C-98DB-4038-A551-07021F75F46D Q28085160-1181E570-B0DB-4729-8922-AB5803CED407 Q28550275-1B5D06D8-F55C-478E-824D-C7C452DB82AC Q28585816-34F863D6-F877-442C-BF54-71E98DEDD32F Q30235979-901543C8-DCF1-4FB7-9C31-7DCFC6705C9F Q30251498-05111065-864C-4C56-8FC0-5809EEB4F0CC Q30315301-FA3FE303-7480-4F94-A767-6214AFAA6921 Q31125419-35A0128C-94AA-4E12-AE14-036B0BF90111 Q31140924-A5E5E293-D543-4D36-8A25-ED9E41F27B05 Q33433527-67B411BB-2505-4B52-9C7B-00CAE61A70C1 Q33434752-8FDFA118-1546-43CE-9F1B-821FC8267C5C Q33584169-99D95A09-41A7-4414-96BF-4B5E75DF405A Q33602076-FBCDF9E6-008F-4319-B44D-63421CBE472F

P2860

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

http://www.wikidata.org/entity/Q33423263

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

@ast

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

@en

type

label

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

@ast

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

@en

prefLabel

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

@ast

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

@en

P1433

Q33423263-D21FF1DC-8328-4A5C-A22F-543F50DA85DD

P1476

Q33423263-94C8FBF1-7C6B-47E3-80E4-A6F0DF1A013F

P2093

Q33423263-102AC8A8-80C4-49D9-9DA6-7A2A0FFC97B8

Q33423263-1347C1B2-62A8-4DEC-A93F-7BD79F373B80

Q33423263-3C970728-F881-4D78-9B5A-6EC09DE92815

Q33423263-606F86E2-F0EC-44BB-AD0A-835DC38AF86D

Q33423263-72BCF724-9600-4C3C-B568-18C187198598

Q33423263-8B3C1256-6AA3-4D96-BB52-174E03E980A9

Q33423263-B90AB008-7973-438D-B6F0-D309105412C9

Q33423263-BA5928FD-7A0A-4ABB-A76F-9315B9F46503

Q33423263-C367CB5C-5CE9-4E0B-8DCA-36608089A02C

Q33423263-CD53E728-30E5-4DA0-A41A-E49DFBAF49CF

P304

Q33423263-49172070-B250-41B8-A538-E16E7FF92B1C

P31

Q33423263-545B5367-ECE3-4DB6-AEE1-EB356894E015

P356

Q33423263-1003F735-3F6B-43BC-AA3E-DF1C07E004D2

P407

Q33423263-63FAA43C-8D1C-4C48-B151-67A7F8D0AE08

P433

Q33423263-0BD9BBF8-B9D8-4369-8B7B-E613F78020D3

P478

Q33423263-196BF04B-2BB6-42E8-832B-268ED2043310

P50

Q33423263-00EB8DBE-AE48-4383-8EF3-7D2B9199D28A

Q33423263-01E3AA33-F0AE-41F9-B4C9-E6D03A4578C0

Q33423263-3D36CF28-ED06-4F1B-A320-94C8EBD9B5EA

Q33423263-F63D5FC6-0194-4A22-8DE8-51C7E06AEE19

P577

Q33423263-3E1A9843-0237-40D5-B2FA-C51B86A77637

P5875

Q33423263-25EF68EB-3C85-4A90-894D-A4C1872FEF3A

P698

Q33423263-8DD5713F-4E90-47E9-8ACB-4D72F4E4836D

P921

Q33423263-A22B660B-7CE2-4262-A55C-9CAF5DD718F1

P356

P1433

The New England Journal of Medicine

P1476

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

@en

P2093

Carla Giorgetti

http://www.w3.org/2001/XMLSchema#string

Cynthia Huang Bartlett

http://www.w3.org/2001/XMLSchema#string

Hiroji Iwata

http://www.w3.org/2001/XMLSchema#string

Jungsil Ro

http://www.w3.org/2001/XMLSchema#string

Ke Zhang

http://www.w3.org/2001/XMLSchema#string

Maria Koehler

http://www.w3.org/2001/XMLSchema#string

Massimo Cristofanilli

http://www.w3.org/2001/XMLSchema#string

Nicholas C Turner

http://www.w3.org/2001/XMLSchema#string

PALOMA3 Study Group

http://www.w3.org/2001/XMLSchema#string

Sophia Randolph

http://www.w3.org/2001/XMLSchema#string

P304

209-219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1505270

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277601946

http://www.w3.org/2001/XMLSchema#string

P698

26030518

http://www.w3.org/2001/XMLSchema#string

P921